The proportion and abundance of PD‐L1 expression in tumor tissue may partially determine the benefits of immune checkpoint therapy.[47] In hepatoma, anti‐PD‐1 immunotherapy can abolish the tumor‐promoting effect induced by upregulated PD‐L1 expression in vivo. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.